<DOC>
	<DOCNO>NCT02347904</DOCNO>
	<brief_summary>In prospective single arm study investigator assess feasibility S-1 Oxaliplatin adjuvant treatment patient esophageal cancer . The primary objective ass feasibility administer adjuvant S-1 Oxaliplatin ( SOX ) patient esophageal cancer neoadjuvant chemoradiotherapy paclitaxel carboplatin esophagectomy . Primary end point percentage patient complete preplanned number 6 cycle SOX .</brief_summary>
	<brief_title>Feasibility Study Adjuvant Treatment With S-1 Oxaliplatin Patients With Resectable Esophageal Cancer</brief_title>
	<detailed_description>Since outcome patient esophageal cancer treat neoadjuvant chemoradiation surgery still poor , strategy improve survival explore . The benefit adjuvant chemotherapy neoadjuvant chemoradiotherapy follow surgery unknown . Preferably , adjuvant chemotherapy regimen consist non-cross resistant , well-tolerated schedule . For purpose , combination S-1 , oral fluoropyrimidine , oxaliplatin , may benefit , compound show efficacy gastroesophageal cancer . Also , importantly , combination S-1 oxaliplatin ( SOX ) advance gastric cancer well-tolerated . Nevertheless , acknowledge major surgery esophageal cancer , adjuvant treatment combination chemotherapy may hard accomplish show MAGIC trial gastric cancer less half patient complete adjuvant therapy . Therefore investigator want assess feasibility adjuvant treatment scheme S-1 Oxaliplatin . When propose treatment scheme feasible potential benefit survival evaluate study . Feasibility define ≥50 % patient complete pre-planned number cycle Study Objectives Primary Objective To assess feasibility administer adjuvant SOX patient esophageal cancer neoadjuvant chemoradiotherapy paclitaxel carboplatin esophagectomy Secondary Objectives 1 . Percentage patient complete 6 cycle S-1 ( without oxaliplatin ) . 2 . Dose modification ( ie , delay , dose reduction , interruption ) S-1 . 3 . Dose modification ( ie , delay , dose reduction , interruption ) oxaliplatin . 4 . Dose intensity S-1 . 5 . Dose intensity oxaliplatin . 6 . Toxicity . 7 . Disease free survival . Exploratory Objectives 1 . Assessment pharmacokinetics S1 predictive factor efficacy toxicity . 2 . Potential biomarker development base assessment archive tumor tissue blood sample propose mechanism action study drug .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Radically resect adenocarcinoma esophagus Completed neoadjuvant treatment paclitaxel 50 mg/m2 carboplatin Area Under Curve ( AUC ) = 2 day 1 , 8 , 15 , 22 29 radiotherapy total dose 41.4 Gy 23 fraction 1.8 Gy , 5 fraction per week . Age ≥ 18 year WHO performance status 01 Adequate bone marrow function ( Hb ≥ 6.0 mmol/L , absolute neutrophil count ≥1.0 x 109/L , platelet ≥ 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , ≥30 ml/min ) , liver function ( serum bilirubin ≤ 2 x Upper Limit Normal ( ULN ) , serum transaminase ≤ 3 x ) . Negative pregnancy test woman childbearing potential . Expected adequacy followup . Written informed consent . Any history clinical sign metastasis History second malignancy &lt; 5 year exception adequately treat carcinoma cervix basal/squamous cell carcinoma skin . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency treatment within 4 week DPD inhibitor , include sorivudine chemically related analogue brivudine . Significant cardiovascular disease &lt; 1 yr start study ( symptomatic congestive heart failure , myocardial ischemia infarction , unstable angina pectoris , serious uncontrolled cardiac arrhythmia , arterial thrombosis , cerebrovascular event , pulmonary embolism ) . Chronic active infection . Any concurrent severe uncontrolled disease prevent safe administration study drug . Any impairment gastrointestinal function disease may significantly impair absorption oral drug ( i.e . uncontrolled nausea , vomit , diarrhoea ( define CTC grade 2 high ) , malabsorption syndrome , bowel obstruction , inability swallow tablet ) . Concomitant treatment : concomitant ( within 4 week start study ) administration experimental drug investigation ; concurrent treatment anticancer therapy . Continuous use systemic immunosuppressive agent ( except use corticosteroid antiemetic prophylaxis/treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Adjuvant treatment</keyword>
	<keyword>S-1</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Feasibility</keyword>
</DOC>